Is Entrada Therapeutics Inc (TRDA) overvalued? · P/E 12, rev $210.8M
Entrada Therapeutics Inc (TRDA) is a biotechnology company listed on US.
This page asks whether Entrada Therapeutics Inc (TRDA) looks expensive on cached numbers — not a short thesis.
Latest reported TRDA revenue for 2024-12-31 was $210.8M. Net income was $65.6M. Revenue was up 63.4% from 2023-12-31 to 2024-12-31. TRDA currently screens at market cap $274.4M and trailing P/E 12.5.
TRDA currently screens at market cap $274.4M and trailing P/E 12.5. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next TRDA 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the TRDA stock page for the full model, not this heading.
Not investment advice.